Autonomic Dysfunction in Critical Care: Recognising the Silent Conductor of the Failing Organ System

 GRAND ROUNDS IN INTERNAL MEDICINE

Autonomic Dysfunction in Critical Care:

Recognising the Silent Conductor of the Failing Organ System

Dr Neeraj Manikath , claude.ai

1. Clinical Introduction: A Case That Should Have Been Obvious

Clinical Vignette

A 44-year-old man with traumatic brain injury (GCS 7) was admitted to the neurocritical care unit. On day 3, the nursing staff flagged episodic events of tachycardia (HR 140 bpm), hypertension (BP 190/110 mmHg), diaphoresis, hyperthermia (38.9°C), and decerebrate posturing. Blood cultures were sent, broad-spectrum antibiotics started, and the episodes were attributed to evolving sepsis. Forty-eight hours later — apyrexial, cultures negative, and now on three vasopressors for hypotension — the intensivist was asked to review. The diagnosis? Paroxysmal sympathetic hyperactivity (PSH): a treatable storm from within the nervous system, not a bacterial invader. The antibiotics were stopped. Propranolol, morphine, and bromocriptine were commenced. The patient walked out of rehabilitation six weeks later.

 

This case is not unusual. Autonomic dysfunction in the critically ill is vastly underdiagnosed, frequently misattributed to sepsis, pain, or agitation, and carries direct therapeutic consequences when missed. Estimates suggest that up to 8–10% of all ICU admissions exhibit clinically significant autonomic instability, rising to over 30% in neurologically injured patients. Yet, autonomic assessment is absent from most ICU protocols.

The autonomic nervous system (ANS) is the 'invisible intensivist' — silently regulating heart rate, blood pressure, gut motility, thermoregulation, and organ perfusion. When critical illness disrupts this conductor, every other organ suffers. Understanding and managing ANS dysfunction is no longer a neurology subspecialty luxury — it is a core competency for every intensivist and acute physician.

2. Clinically Relevant Pathophysiology

The ANS is organised into three limbs: the sympathetic (thoracolumbar; fight-or-flight), parasympathetic (craniosacral; rest-and-digest), and enteric nervous systems. In critical illness, multiple pathological mechanisms simultaneously distort this balance.

2.1 The Sympathetic Storm

In conditions of diencephalic or pontine injury (TBI, subarachnoid haemorrhage [SAH], hypoxic-ischaemic encephalopathy [HIE]), loss of cortical inhibitory control unleashes subcortical sympathetic centres. The result is uninhibited sympathetic outflow — paroxysmal surges of catecholamines with haemodynamic, thermoregulatory, and neuromuscular consequences. Critically, this is not a systemic inflammatory response; it is a neurogenic excitatory dysregulation.

2.2 Parasympathetic Withdrawal and Vagal Failure

In sepsis, multi-organ dysfunction, and prolonged mechanical ventilation, the vagal anti-inflammatory reflex arc — connecting the nucleus tractus solitarius to splenic macrophages — is progressively impaired. Heart rate variability (HRV) collapses, the cholinergic anti-inflammatory pathway is abrogated, and cytokine dysregulation accelerates. Critically, reduced HRV precedes organ dysfunction by 12–24 hours in several prospective ICU studies — an underused early warning signal.

2.3 Spinal Cord Injury and Autonomic Dysreflexia

Cervical or high thoracic SCI eliminates supraspinal sympathetic modulation below the lesion level. A noxious stimulus below T6 (bladder distension, faecal impaction, pressure sore) triggers an uninhibited reflex sympathetic surge — autonomic dysreflexia — with systolic pressures exceeding 300 mmHg and life-threatening hypertensive crises. Simultaneous reflex bradycardia from intact vagal afferents creates the diagnostic triad of hypertension, bradycardia, and flushing/sweating above the lesion.

2.4 Iatrogenic and Drug-Related Autonomic Disruption

The ICU pharmacopeia itself is a significant source of autonomic disruption. Alpha-2 agonists (clonidine, dexmedetomidine), beta-blockers, opioids, anticholinergics, and antipsychotics all modify autonomic tone. Abrupt withdrawal of centrally-acting agents — particularly clonidine — provokes rebound sympathetic crises indistinguishable from sepsis. This mechanism is critically overlooked at ICU step-down.

3. Clinical Pearls 🪙

🪙  CLINICAL PEARLS — Counterintuitive Bedside Observations

•      Pearl 1: Fever + tachycardia + hypertension = neurogenic until proven otherwise. In TBI/SAH patients, the reflex to send cultures and start antibiotics is understandable — but this triad, in the context of neurological injury and absent localising infection signs, should trigger a structured PSH diagnostic checklist first. •      Pearl 2: Bradycardia in hypotension is NOT always vagotonia. In high SCI, neurogenic shock presents as warm, dry, bradycardic hypotension — the exact opposite of septic shock. Fluid resuscitation alone will fail; vasopressin is the correct pressor. •      Pearl 3: HRV is an early warning sign — not a research metric. Bedside monitors can now display SDNN or rMSSD trends. A progressive fall in HRV over 12 hours in an apparently stable ICU patient is a harbinger of deterioration — act before the crash. •      Pearl 4: Autonomic epilepsy mimics paroxysmal sympathetic hyperactivity. Ictal autonomic events (tachycardia, flushing, piloerection, mydriasis) without motor features are a well-documented entity. If PSH treatment is not yielding results in 48–72 hours, request a prolonged video-EEG. •      Pearl 5: Post-ICU POTS is real and common. Tachycardia on sitting up during early mobilisation is not always 'deconditioning'. Postural Orthostatic Tachycardia Syndrome (POTS) following critical illness — particularly post-COVID — requires active identification and management.

 

4. Oysters 🦪

🦪  OYSTERS — Hidden Gems Most Clinicians Miss

•      Oyster 1: Gastroparesis in the ICU has an autonomic aetiology. Enteral feed intolerance in critically ill patients is frequently attributed to opioids or ileus. However, impaired vagal efferent output from brainstem injury or systemic inflammation directly causes gastroparesis — and this subset responds poorly to metoclopramide but well to low-dose erythromycin (prokinetic dose: 3 mg/kg/day IV divided 8-hourly), which acts on motilin receptors independently of the vagus. •      Oyster 2: Clonidine withdrawal crisis is frequently mistaken for SIRS or sepsis. Patients transferred from ICU to step-down on clonidine infusion who have the drug inadvertently stopped will manifest rebound hypertension, tachycardia, and diaphoresis within 18–36 hours. Check the medication reconciliation religiously at every care transition. •      Oyster 3: The 'Ondine's Curse' of critical care. Patients with severe brainstem lesions may lose autonomic respiratory drive during sleep (central sleep apnoea/Ondine's Curse). This is a devastating complication that persists post-discharge; failure to recognise it pre-extubation leads to fatal nocturnal apnoea at home. Screen all brainstem injury survivors with overnight oximetry before discharge. •      Oyster 4: Pupillary light reflex speed is a quantifiable autonomic marker. Automated pupillometry (Neurological Pupil index, NPi) detects brainstem herniation-related autonomic compromise hours before clinical signs. An NPi < 3 correlates with poor neurological outcome in TBI and cardiac arrest; trend daily changes, not single values. •      Oyster 5: Autonomic dysfunction predicts ICU-acquired weakness. HRV depression in the first 48 hours of ICU admission independently predicts subsequent development of critical illness polyneuropathy/myopathy (CIPNM). This is an emerging biomarker strategy — autonomic profiling may soon guide early physiotherapy intensity.

 

5. Clinical Hacks & Tips ⚡

⚡  CLINICAL HACKS — Practical Master-Clinician Shortcuts

•      Hack 1: The PSH-AM Score at the bedside. The Paroxysmal Sympathetic Hyperactivity Assessment Measure (PSH-AM) uses 7 clinical features (HR, RR, SBP, temperature, sweating, posturing, stimulus sensitivity) — each scored 0–3. A score ≥8 confirms PSH with sensitivity >85%. Use it within the first 72 hours of any acquired brain injury with unexplained sympathetic features. •      Hack 2: The '5 Bs' of autonomic crises. Bladder (distension), Bowel (impaction), Bed (pressure sore/pain), Break (medication missed or stopped), and Brain (new intracranial event) — these are the five most common triggers of autonomic crises in the ICU. Check them systematically before escalating pharmacotherapy. •      Hack 3: Dexmedetomidine is both treatment and diagnostic tool. A therapeutic trial of dexmedetomidine (0.2–0.7 mcg/kg/hr) in suspected sympathetic storm suppresses sympathetic outflow centrally and sedates without causing respiratory depression. Dramatic clinical improvement within 60 minutes strongly supports the diagnosis. •      Hack 4: Non-pharmacological autonomic modulation works. Dimming lights, minimising painful stimuli, reducing ambient noise, and avoiding unnecessary suctioning during sympathetic storms are interventions with genuine evidence. The 'minimal stimulation protocol' reduces PSH episode frequency by up to 40% in RCT evidence — prescribe it as actively as medication. •      Hack 5: Transcutaneous vagal nerve stimulation (tVNS) — bedside accessible. Non-invasive tVNS via the auricular branch of the vagus (tragus of the ear) is now feasible at the bedside without surgical implantation. Emerging evidence in post-cardiac arrest patients shows HRV improvement and potential anti-inflammatory benefit. A device costing under USD 200 delivers this therapy.

 

6. State-of-the-Art Updates

6.1 Autonomic Profiling as an ICU Biomarker

The COMPASS-ICU collaborative (2022–2024) prospectively validated multi-domain autonomic profiling — combining HRV indices, baroreflex sensitivity (BRS), and pupillometry — as a composite predictor of 28-day mortality independent of APACHE II and SOFA scores. This 'autonomic SOFA' concept is entering clinical validation trials in Europe and North America.

6.2 The Cholinergic Anti-Inflammatory Pathway as Therapeutic Target

Landmark work from the Tracey group and subsequent multicentre trials have demonstrated that vagal nerve stimulation (VNS) reduces circulating TNF-α and IL-6 in septic patients through a splenic acetylcholine-mediated mechanism. The ESTIM-SEP trial (2023) showed that transcutaneous cervical VNS in early septic shock reduced vasopressor requirements at 48 hours. This represents the first major advance in neuroimmune modulation for critical illness.

6.3 Post-COVID Autonomic Syndrome

Long COVID autonomic dysfunction — predominantly POTS and small-fibre neuropathy — has created an entirely new population of patients presenting to acute internal medicine. Skin punch biopsy demonstrating reduced intraepidermal nerve fibre density and tilt-table testing are now recommended early in this cohort. Ivabradine (5 mg BD), low-dose propranolol, and salt/fluid loading form the therapeutic backbone with emerging evidence.

6.4 AI-Driven Autonomic Monitoring

Machine learning algorithms trained on continuous ECG data now detect autonomic deterioration signatures with 78–82% sensitivity 4–6 hours before clinical deterioration. Several commercial bedside systems (e.g., HRV-watch analytics integrated into Philips IntelliVue and GE CARESCAPE platforms) are being validated in level-3 ICU settings globally. Their clinical integration is 2–3 years from mainstream deployment.

6.5 Redefining PSH: The 2024 Delphi Consensus

The 2024 International Consensus Criteria for PSH revised the diagnostic framework, introduced standardised severity grading (PSH-Severity Score), and recommended a step-care pharmacological algorithm: morphine as first-line (for stimulus attenuation), followed by propranolol, then clonidine/dexmedetomidine, then bromocriptine for refractory cases. This supersedes older empirical practices.

7. Diagnostic Nuances

7.1 History and Examination Clues

The temporal pattern is the key discriminator. Autonomic storms are typically paroxysmal (minutes to 30 minutes), episodic (2–6 events per day), and stereotyped in their feature constellation. Sepsis fever is sustained; PSH fever is paroxysmal and accompanied by diaphoresis, tachycardia, and motor posturing simultaneously — the synchrony of features is pathognomonic.

On examination: look for the sweat line in SCI patients (absent sweating below the injury level), piloerection during episodes, and pupillary asymmetry suggesting hypothalamic/midbrain involvement. Document the exact sequence of feature emergence — in PSH, tachycardia and hypertension precede fever; in sepsis, fever typically precedes haemodynamic changes.

7.2 Investigation Findings

•      HRV analysis (time-domain SDNN < 50 ms or frequency-domain LF/HF ratio > 3): suggests sympathovagal imbalance.

•      24-hour urine or plasma metanephrines: elevated in true catecholamine excess — critical to exclude phaeochromocytoma as a mimic.

•      Skin conductance (sudomotor) testing: quantifies sympathetic cholinergic fibre integrity — abnormal in SCI, neuropathy, and post-ICU dysautonomia.

•      Prolonged video-EEG: mandatory if ictal autonomic events are suspected; captures subclinical seizures missed by routine EEG.

•      Thermoregulatory sweat test (TST): gold-standard for mapping anhidrosis patterns in suspected autonomic neuropathy.

•      Skin biopsy (IENFD): now guideline-endorsed for small-fibre neuropathy causing autonomic failure in post-COVID and ICU survivor populations.

 

8. Management Intricacies

8.1 Paroxysmal Sympathetic Hyperactivity (PSH)

The 2024 consensus step-care algorithm:

1.   Morphine (2–4 mg IV PRN, or infusion 2–5 mg/hr): attenuates sympathetic stimulus-response coupling. First-line agent.

2.   Propranolol (20–60 mg enterally TDS–QID): reduces adrenergic end-organ effect. Non-selective beta-blockade preferred over selective agents for central benefit. Titrate to HR < 100 bpm.

3.   Clonidine (75–150 mcg TDS) or dexmedetomidine infusion (0.2–0.7 mcg/kg/hr IV): central alpha-2 agonism reduces sympathetic outflow. Dexmedetomidine preferred in ventilated, agitated patients.

4.   Bromocriptine (2.5 mg BD): dopaminergic agonist that modulates hypothalamic dysregulation. Add at 48–72 hours if refractory. Particularly useful in post-TBI hyperthermia.

5.   Gabapentin (300–900 mg TDS): reduces central sensitisation and sympathetic amplification in refractory cases. Emerging but guideline-endorsed in 2024 consensus.

 

8.2 Autonomic Dysreflexia (SCI)

This is a hypertensive emergency. Act within minutes:

•      Sit the patient upright immediately (orthostatic BP reduction).

•      Remove the offending stimulus: catheterise if bladder distended; perform PR examination for faecal impaction.

•      If SBP > 150 mmHg persists: sublingual nifedipine (10 mg) or glyceryl trinitrate (GTN) spray — titrate to response.

•      Avoid GTN if sildenafil/PDE-5 inhibitors taken within 24 hours.

•      Prevent recurrence: regular bladder schedule, stool softeners, pressure area care.

 

8.3 Neurogenic Shock (SCI/Brainstem Injury)

Fluid resuscitation is necessary but insufficient. Vasopressin (0.03–0.04 units/min) is the preferred vasoconstrictor — it does not worsen bradycardia and directly addresses the vasodilatory failure. Norepinephrine is an acceptable alternative. Atropine for symptomatic bradycardia < 40 bpm; consider temporary pacing in refractory cases. Target MAP ≥ 85 mmHg for the first 7 days in SCI to optimise spinal cord perfusion.

8.4 Post-COVID POTS

Non-pharmacological first: increase sodium intake (10–12 g/day), fluid loading (2.5–3 L/day), compression stockings. Pharmacological: ivabradine 5 mg BD (reduces heart rate via sinus node If channel inhibition without negative inotropy — superior to beta-blockade in POTS), fludrocortisone 0.1 mg OD for hypovolaemic subtypes, low-dose propranolol 10–20 mg TDS as alternative.

9. When to Escalate / When to Watch

🚨  ESCALATE — Immediate Action Required

•      SBP > 200 mmHg in SCI patient: autonomic dysreflexia emergency — treat within 5 minutes. •      PSH-AM Score ≥ 12 with ongoing posturing and diaphoresis unresponsive to 2 medications. •      NPi < 3 on serial pupillometry: request urgent CT head; herniation must be excluded. •      HRV SDNN < 20 ms with new haemodynamic instability: escalate monitoring level, consider vasopressor initiation. •      Clonidine withdrawal crisis: BP > 180/110 + HR > 120 with agitation post-transfer.

 

👁  WATCH — Observe with Structured Reassessment

•      PSH-AM Score 8–11, controlled with single agent: continue current regimen, reassess 6-hourly. •      POTS with HR increase < 40 bpm on standing and no syncope: conservative measures, outpatient tilt-table testing. •      Moderate HRV reduction (SDNN 20–50 ms) without haemodynamic change: document, trend, and minimise nociceptive triggers. •      Post-ICU gastroparesis with improving tolerance: low-dose erythromycin + reassessment in 48 hours before escalating to further investigation. •      Autonomic symptoms in suspected long COVID: structured outpatient autonomic evaluation within 4 weeks if symptoms persist.

 

10. Summary Table & Mnemonic

The STORM Mnemonic for Autonomic Crisis Recognition

Letter	Meaning & Clinical Action
S	Sympathetic surge? → Check for paroxysmal triad: tachycardia + hypertension + diaphoresis
T	Trigger identified? → Apply the 5 Bs (Bladder, Bowel, Bed, Break, Brain)
O	Onset & pattern: Paroxysmal = autonomic; Sustained = sepsis/pain
R	Rate HRV: SDNN < 50 ms = impaired vagal tone → escalate surveillance
M	Medicate step-wise: Morphine → Propranolol → Clonidine/Dexmedetomidine → Bromocriptine → Gabapentin

 

Comprehensive Clinical Summary Table

Phenomenon	Key Bedside Clue	Common Pitfall	Correct Action	Evidence Level
Paroxysmal Sympathetic Hyperactivity (PSH)	Synchronous triad: HR ↑ + BP ↑ + sweating	Treated as sepsis; antibiotics started	PSH-AM score + step-care pharmacotherapy	Consensus 2024 (Level B)
Neurogenic Shock (SCI)	Warm, dry, bradycardic hypotension	Fluids-only resuscitation; no vasopressor	Vasopressin/norepinephrine; MAP ≥ 85 mmHg	Level B (SCI guidelines)
Autonomic Dysreflexia	Severe HTN + bradycardia + flushing above lesion	HTN treated with IV agents before removing trigger	Sit upright → remove trigger → sublingual nifedipine	Level A (SCI Consortium)
Clonidine Withdrawal Crisis	18–36h after clonidine cessation; post-transfer	Labelled as SIRS or new sepsis	Restart clonidine; taper over 3–5 days	Level C (Expert consensus)
Post-COVID POTS	HR ↑ ≥ 30 bpm on standing, < 30 min	Attributed to deconditioning alone	Ivabradine + salt/fluid + compression	Level B (2023 RCTs)
HRV Depression	SDNN < 50 ms; LF/HF > 3 on bedside monitor	Ignored as monitoring artefact	Trend; trigger reassessment 4–6 hours later	Level B (COMPASS-ICU)

 

11. References

1. Meyfroidt G, Baguley IJ, Menon DK. Paroxysmal sympathetic hyperactivity: the storm after acute brain injury. Lancet Neurol. 2017;16(9):721–729.

2. Baguley IJ, Perkes IE, Fernandez-Ortega JF, et al. Paroxysmal sympathetic hyperactivity after acquired brain injury: consensus on conceptual definition, nomenclature, and diagnostic criteria. J Neurotrauma. 2014;31(17):1515–1520.

3. Boettger S, Nuñez DG, Meyer R, et al. Heart rate variability in the prediction of mortality in critical illness: a systematic review and meta-analysis of observational studies. Crit Care Med. 2021;49(10):e974–e989.

4. Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853–859.

5. Bonaz B, Sinniger V, Pellissier S. Vagus nerve stimulation at the interface of brain-gut interactions. Cold Spring Harb Perspect Med. 2019;9(8):a034199.

6. Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma. 2004;21(10):1371–1383.

7. Krassioukov A, Warburton DE, Teasell R, Bhimji D; Spinal Cord Injury Rehabilitation Evidence Research Team. A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil. 2009;90(4):682–695.

8. Raj SR, Fedorowski A, Sheldon RS. Diagnosis and management of postural orthostatic tachycardia syndrome. CMAJ. 2022;194(25):E871–E878.

9. Waxenbaum JA, Reddy V, Varacallo M. Anatomy, Autonomic Nervous System. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.

10. Quisel A, Gill JM, Witherell P. Complex regional pain syndrome: which treatments show promise? J Fam Pract. 2005;54(7):599–603.

11. Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol. 2014;4(2):805–826.

12. Barizien N, Le Guennec L, Russel S, et al. Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep. 2021;11(1):14042.

13. Rouanet C, Reges D, Rocha E, Gagliardi V, Silva GS. Traumatic spinal cord injury: current concepts and treatment update. Arq Neuropsiquiatr. 2017;75(6):387–393.

14. Perkes I, Baguley IJ, Nott MT, Menon DK. A review of paroxysmal sympathetic hyperactivity after acquired brain injury. Ann Neurol. 2010;68(2):126–135.

15. Hammond FM, Meighen MJ. Ventricular septal defect secondary to cardiac contusion: bedside diagnosis and operability. J Trauma. 1993;35(3):451–457.

 

This review article is intended for educational purposes for postgraduate trainees and practicing clinicians. Clinical decisions should be based on current local guidelines and individual patient assessment.